Haemodialysis — adequacy and chronic complications
HD adequacy · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Maintenance haemodialysis requires adequate solute clearance (Kt/V), volume and symptom control, plus management of intradialytic complications and long-term sequelae. Adequacy targets and dry-weight assessment underpin good outcomes.
Red flags
- Catheter-related bloodstream infection (fever, rigors on dialysis)
- Severe intradialytic hypotension or arrhythmia
- Access haemorrhage or thrombosis
- Signs of under-dialysis: pericarditis, encephalopathy
- Severe hyperkalaemia pre-dialysis with ECG changes
Assessment
Differential diagnosis
- Inadequate dialysis (low Kt/V, access recirculation)
- Intradialytic hypotension
- Volume overload / under-dialysis
- Access dysfunction
- Anaemia/CKD-MBD contributing to symptoms
- Uraemia from missed sessions
Investigations
- Monthly urea reduction ratio and single-pool Kt/V (target spKt/V >=1.2 or URR >=65%)
- Pre/post dialysis weights and interdialytic weight gain
- U&E, calcium, phosphate, PTH, bicarbonate
- Haemoglobin, ferritin, TSAT
- Access surveillance (flow, pressures, recirculation)
- Hepatitis B/C and vaccination status
Management
- Prescribe dialysis dose to achieve spKt/V >=1.2 (thrice-weekly), adjusting time, blood/dialysate flow and dialyser
- Assess and set dry weight clinically (and with bioimpedance/lung ultrasound where available) to control volume
- Limit interdialytic weight gain with sodium/fluid restriction and dietary counselling
- Manage intradialytic hypotension: reassess dry weight, cooler dialysate, slower ultrafiltration, avoid pre-dialysis antihypertensives/eating
- Monitor and treat CKD-MBD, renal anaemia and metabolic acidosis per targets
- Surveil vascular access and refer early for dysfunction/stenosis
- Ensure infection prevention: minimise catheter use, hepatitis B vaccination, exit-site care
- Review medications for dialysability and timing (give phosphate binders, hold hypotensives as needed)
- Address cardiovascular risk and sudden-death risk (avoid large potassium/fluid shifts)
- Provide dietary potassium/phosphate/fluid education
- Assess for transplant candidacy and home dialysis options
- Review adequacy, volume status and complications at regular multidisciplinary clinics
Drugs & doses
Erythropoiesis-stimulating agent (e.g. darbepoetin 0.45 micrograms/kg SC weekly) titrated to Hb 100-120 g/L
IV iron sucrose 200 mg per session as needed to maintain iron stores
Phosphate binder with meals (e.g. sevelamer 800-2400 mg PO TDS)
Cinacalcet 30-180 mg PO daily or etelcalcetide IV for secondary hyperparathyroidism
Alteplase 2 mg per lumen for catheter thrombosis (locking)
Midodrine 2.5-10 mg PO pre-dialysis for refractory intradialytic hypotension
Disposition
Maintenance haemodialysis unit with multidisciplinary follow-up. Admit for access infection, severe hypotension or under-dialysis complications. Transplant assessment where eligible.
Complications & pitfalls
- Intradialytic hypotension and cardiovascular events
- Access thrombosis/stenosis/infection
- Dialysis-related amyloidosis
- Malnutrition-inflammation complex
- Catheter-related bloodstream infection
- Sudden cardiac death
Exam pearls
- Target spKt/V >=1.2; low adequacy predicts poor outcomes
- Catheters carry the highest infection and mortality risk — favour fistulas
- Treat intradialytic hypotension by reassessing dry weight, not just fluids
- Minimise interdialytic weight gain to protect the heart
- Longer/more frequent dialysis improves volume and phosphate control
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.